Claims

1. A composition comprising a fusion protein comprising at least two cytokines,

   wherein the cytokines are human chemokine (C motif) ligand (XCL1) and human interferon alpha 2 (IFNα2), and

   wherein at least one cytokine comprises a mutation that reduces binding activity to its receptor as compared to wild type cytokine and at least one cytokine is a wild-type cytokine which provides cell-specific targeting that restores activity of the mutant cytokine on the targeted cells.

2. The composition of claim 1, further comprising a linker.

3. The composition of claim 2, wherein the linker is one or more GSS repeats.

4. The composition of any one of claims 1-3, wherein the human IFNα2 comprises the mutation.

5. The composition of any one of claims 1-4, wherein the wild-type cytokine is human XCL1.

6. A method for stimulating an immune response in a cell, comprising contacting the cell with a composition comprising a composition comprising at least two cytokines,
   wherein the cytokines are human XCL1 and human IFNα2, and
   wherein at least one of the cytokines has a mutation which provides reduced affinity for its receptor as compared to wild type cytokine and at least one cytokine is a wild-type cytokine that provides cell-specific targeting that restores activity of the mutant cytokine on the targeted cells.

7. The method according to claim 6, further comprising a linker.

8. The method according to claim 7, wherein the linker is one or more GSS repeats.

9. The method of any one of claims 6-8, wherein the human IFNα2 comprises the mutation.

10. The method of any one of claims 6-9, wherein the wild-type cytokine is human XCL1.